132 related articles for article (PubMed ID: 32664826)
1. Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response.
Liu W; Takahashi Y; Morishita M; Nishikawa M; Takakura Y
Nanomedicine (Lond); 2020 Jul; 15(17):1641-1652. PubMed ID: 32664826
[No Abstract] [Full Text] [Related]
2. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
Kikuchi T; Moore MA; Crystal RG
Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
[TBL] [Abstract][Full Text] [Related]
3. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
5. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
[TBL] [Abstract][Full Text] [Related]
6. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.
Dotti G; Savoldo B; Takahashi S; Goltsova T; Brown M; Rill D; Rooney C; Brenner M
Exp Hematol; 2001 Aug; 29(8):952-61. PubMed ID: 11495701
[TBL] [Abstract][Full Text] [Related]
7. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
[TBL] [Abstract][Full Text] [Related]
8. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation.
Pinchuk LM; Klaus SJ; Magaletti DM; Pinchuk GV; Norsen JP; Clark EA
J Immunol; 1996 Nov; 157(10):4363-70. PubMed ID: 8906811
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.
Kelsall BL; Stüber E; Neurath M; Strober W
Ann N Y Acad Sci; 1996 Oct; 795():116-26. PubMed ID: 8958922
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.
Brunekreeft KL; Strohm C; Gooden MJ; Rybczynska AA; Nijman HW; Grigoleit GU; Helfrich W; Bremer E; Siegmund D; Wajant H; de Bruyn M
Mol Cancer; 2014 Apr; 13():85. PubMed ID: 24741998
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand.
Vidalain PO; Azocar O; Yagita H; Rabourdin-Combe C; Servet-Delprat C
J Immunol; 2001 Oct; 167(7):3765-72. PubMed ID: 11564793
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
13. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells.
Réthi B; Gogolák P; Szatmari I; Veres A; Erdôs E; Nagy L; Rajnavölgyi E; Terhorst C; Lányi A
Blood; 2006 Apr; 107(7):2821-9. PubMed ID: 16317102
[TBL] [Abstract][Full Text] [Related]
14. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.
Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH
Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233
[TBL] [Abstract][Full Text] [Related]
16. Engaging the CD40-CD40L pathway augments T-helper cell responses and improves control of Mycobacterium tuberculosis infection.
Sia JK; Bizzell E; Madan-Lala R; Rengarajan J
PLoS Pathog; 2017 Aug; 13(8):e1006530. PubMed ID: 28767735
[TBL] [Abstract][Full Text] [Related]
17. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
[TBL] [Abstract][Full Text] [Related]
19. The role of CD40 ligand in costimulation and T-cell activation.
Grewal IS; Flavell RA
Immunol Rev; 1996 Oct; 153():85-106. PubMed ID: 9010720
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
